Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ENTA

ENTA - Enanta Pharmaceuticals Inc Stock Price, Fair Value and News

12.84USD-0.59 (-4.39%)Market Closed

Market Summary

ENTA
USD12.84-0.59
Market Closed
-4.39%

ENTA Stock Price

View Fullscreen

ENTA RSI Chart

ENTA Valuation

Market Cap

271.9M

Price/Earnings (Trailing)

-2.06

Price/Sales (Trailing)

3.73

EV/EBITDA

-1.79

Price/Free Cashflow

-2.4

ENTA Price/Sales (Trailing)

ENTA Profitability

EBT Margin

-178.25%

Return on Equity

-79.3%

Return on Assets

-31.85%

Free Cashflow Yield

-41.66%

ENTA Fundamentals

ENTA Revenue

Revenue (TTM)

72.9M

Rev. Growth (Yr)

-4.16%

Rev. Growth (Qtr)

-5.27%

ENTA Earnings

Earnings (TTM)

-131.7M

Earnings Growth (Yr)

17.26%

Earnings Growth (Qtr)

6.74%

Breaking Down ENTA Revenue

Last 7 days

-0.5%

Last 30 days

-3.7%

Last 90 days

-9.6%

Trailing 12 Months

-46.9%

How does ENTA drawdown profile look like?

ENTA Financial Health

Current Ratio

6.43

ENTA Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-6.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202472.9M000
202381.2M80.6M79.2M73.6M
202291.6M89.4M86.2M82.1M
202194.2M97.1M97.1M93.0M
2020175.9M150.2M122.5M101.6M
2019234.0M221.1M205.2M187.9M
2018165.6M215.3M206.6M238.4M
201746.2M39.7M102.8M130.5M
201687.5M89.8M88.3M50.2M
2015179.6M149.1M160.9M131.8M
20146.1M46.5M47.7M124.3M
201336.9M34.5M32.1M5.1M
20120041.7M39.3M

Tracking the Latest Insider Buys and Sells of Enanta Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 26, 2024
gardiner nathaniel s.
acquired
46,631
8.99
5,187
chief legal officer
Feb 12, 2024
luu brendan
sold (taxes)
-12,074
12.41
-973
chief business officer
Feb 12, 2024
kieffer tara lynn
acquired
-
-
3,320
chief product strategy officer
Feb 12, 2024
luly jay r.
sold (taxes)
-19,657
12.41
-1,584
president and ceo
Feb 12, 2024
mellett paul j
sold (taxes)
-12,074
12.41
-973
chief fin. & admin officer
Feb 12, 2024
gardiner nathaniel s.
sold (taxes)
-12,074
12.41
-973
chief legal officer
Feb 12, 2024
luly jay r.
acquired
-
-
5,400
president and ceo
Feb 12, 2024
luu brendan
acquired
-
-
3,320
chief business officer
Feb 12, 2024
or yat sun
acquired
-
-
3,680
chief scientific officer
Feb 12, 2024
gardiner nathaniel s.
acquired
-
-
3,320
chief legal officer

1–10 of 50

Which funds bought or sold ENTA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
3.46
17,523,400
36,578,700
0.17%
May 20, 2024
Virtu Financial LLC
new
-
191,000
191,000
0.01%
May 16, 2024
COMERICA BANK
new
-
5,814
5,814
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.12
4,588
35,566
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-71.9
-335,252
365,229
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
reduced
-40.12
2,158,320
21,580,600
0.29%
May 15, 2024
DEUTSCHE BANK AG\
added
5.22
91,189
186,945
-%
May 15, 2024
STATE STREET CORP
reduced
-0.39
3,397,160
7,402,430
-%
May 15, 2024
Tudor Investment Corp Et Al
new
-
181,671
181,671
-%
May 15, 2024
MORGAN STANLEY
added
74.34
24,669,800
35,708,200
-%

1–10 of 48

Are Funds Buying or Selling ENTA?

Are funds buying ENTA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ENTA
No. of Funds

Unveiling Enanta Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.80%
2,064,000
SC 13G/A
Feb 13, 2024
vanguard group inc
8.52%
1,793,786
SC 13G/A
Jan 26, 2024
farallon capital partners, l.p.
1.8%
379,200
SC 13G/A
Jan 24, 2024
blackrock inc.
9.2%
1,934,711
SC 13G/A
Jan 22, 2024
state street corp
2.02%
425,640
SC 13G/A
Jan 11, 2024
millennium management llc
6.2%
1,314,949
SC 13G
Nov 16, 2023
millennium management llc
4.9%
1,024,676
SC 13G
Oct 06, 2023
blackrock inc.
9.4%
1,978,011
SC 13G/A
Feb 14, 2023
armistice capital, llc
9.99%
2,078,000
SC 13G
Feb 14, 2023
first manhattan co
1.17%
243,718
SC 13G/A

Recent SEC filings of Enanta Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 08, 2024
S-8
Employee Benefits Plan
May 08, 2024
10-Q
Quarterly Report
May 06, 2024
8-K
Current Report
May 01, 2024
4
Insider Trading
May 01, 2024
3
Insider Trading
Mar 12, 2024
8-K
Current Report
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading

Peers (Alternatives to Enanta Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Enanta Pharmaceuticals Inc News

Latest updates
Defense World09 Jun 202402:58 pm

Enanta Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-5.3%17,054,00018,003,00018,932,00018,892,00017,795,00023,585,00020,317,00019,479,00018,716,00027,648,00023,575,00021,624,00020,132,00031,743,00023,631,00018,653,00027,619,00052,570,00051,313,00044,367,00039,631,000
Costs and Expenses-5.8%49,820,00052,889,00049,962,00055,605,00057,246,00053,598,00047,365,00052,019,00052,563,00058,057,00057,302,00055,471,00049,832,00044,042,00043,414,00041,505,00039,494,00039,699,00044,882,00040,612,00040,935,000
  S&GA Expenses-13.8%14,235,00016,518,00013,795,00012,618,00013,778,00012,696,00012,569,00012,929,00010,476,0009,508,0008,356,0008,477,0008,326,0007,377,0006,728,0006,823,0006,884,0006,921,0006,163,0006,151,0006,780,000
  R&D Expenses-2.2%35,585,00036,371,00036,167,00042,987,00043,468,00040,902,00034,796,00039,090,00042,087,00048,549,00048,946,00046,994,00041,506,00036,665,00036,686,00034,682,00032,610,00032,778,00038,719,00034,461,00034,155,000
EBITDA Margin6.0%-1.59-1.70-1.56-1.53-1.51-1.44-1.38-1.41-1.39-1.32-1.07-0.92---------
Interest Expenses-25.5%2,563,0003,441,0003,151,0001,997,000-----------------
Income Taxes41.6%-363,000-622,000-1,410,0004,221,00044,000-34,00032,000-447,000--36,000-15,905,000-9,384,0007,110,000-3,294,00010,707,000-7,142,000-3,920,0001,504,000-486,000-866,000-3,204,000
Earnings Before Taxes7.4%-31,520,000-34,029,000-29,517,000-34,844,000-37,614,000-29,020,000-26,316,000-32,147,000-33,592,000-30,151,000-33,394,000-33,408,000-29,155,000-11,622,000-18,634,000-21,407,000-9,925,00014,947,0008,705,0006,170,000941,000
EBT Margin3.5%-1.78-1.85-1.65-1.59-1.54-1.47-1.42-1.45-1.43-1.36-1.11-0.96---------
Net Income6.7%-31,157,000-33,407,000-28,107,000-39,065,000-37,658,000-28,986,000-26,348,000-31,700,000-33,592,000-30,115,000-24,599,000-24,024,000-22,045,000-8,328,000-29,341,000-14,265,000-6,005,00013,443,0009,191,0007,036,0004,145,000
Net Income Margin3.7%-1.81-1.88-1.69-1.64-1.54-1.47-1.41-1.34-1.23-1.08-0.81-0.86---------
Free Cashflow-17.4%-30,269,000-25,775,000-22,970,000-34,279,000-16,166,000-38,797,000-16,971,000-29,853,000-26,449,000-13,634,000-21,054,000-29,905,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-3.5%414428462495326348375385407441439450468481486512514511490473462
  Current Assets-10.1%351390423448271284312313342327319321428446437413403441402451424
    Cash Equivalents59.1%64.0040.0085.0095.0073.0042.0044.0028.0041.0099.0057.005.0077.0055.0087.0010074.0028.0051.0094.00106
  Net PPE27.7%15.0012.0012.0012.0011.009.006.005.005.005.006.007.007.008.009.009.0010.0010.0011.0011.0011.00
Liabilities4.6%24723724625757.0047.0054.0047.0048.0056.0039.0033.0032.0029.0031.0031.0028.0029.0027.0025.0025.00
  Current Liabilities-12.5%55.0062.0063.0068.0032.0023.0030.0023.0031.0038.0036.0029.0027.0023.0024.0024.0020.0019.0023.0021.0020.00
Shareholder's Equity-13.4%166192217238269301321338359384399418436452456481486482462448436
  Retained Earnings-13.0%-271-240-206-178-139-102-73.18-46.83-15.1318.0049.0073.0097.00119128157171177164155148
  Additional Paid-In Capital1.3%438433425418411405398388377367351345339332327322314305298293289
Shares Outstanding0.1%21.0021.0021.0021.0021.0021.0021.0021.0021.0020.0020.0020.00---------
Float-----800---1,262---865---754---1,408
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-14.5%-28,601-24,988-21,602-32,128-13,783-35,641-15,534-29,602-26,375-13,271-21,021-29,506-4,579-14,890-15,461-4,48814,67412,3638,5452,53330,086
  Share Based Compensation-31.3%5,5618,0996,7166,9987,3637,1396,8337,6036,4716,0625,3535,4755,2804,8834,7454,7544,9785,0984,5124,1644,707
Cashflow From Investing546.9%58,624-13,11711,836-145,74846,76533,56928,23116,220-35,05545,50172,683-43,70525,458-17,4452,50426,77927,748-37,201-52,208-14,8471,322
Cashflow From Financing12.7%-6,414-7,350-23.00199,875-2,0273012,9304,1203,3519,6329436861,1522992333,2264,3581,166687490257
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ENTA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 17,054$ 17,795$ 35,057$ 41,380
Operating expenses:    
Research and development35,58543,46871,95684,370
General and administrative14,23513,77830,75326,474
Total operating expenses49,82057,246102,709110,844
Loss from operations(32,766)(39,451)(67,652)(69,464)
Other income (expense):    
Interest expense(2,563)0(6,004)0
Interest and investment income, net3,8091,8378,1072,830
Total other income, net1,2461,8372,1032,830
Loss before income taxes(31,520)(37,614)(65,549)(66,634)
Income tax benefit (expense)363(44)985(10)
Net loss$ (31,157)$ (37,658)$ (64,564)$ (66,644)
Net loss per share:    
Basic$ (1.47)$ (1.79)$ (3.06)$ (3.19)
Diluted$ (1.47)$ (1.79)$ (3.06)$ (3.19)
Weighted average shares outstanding:    
Basic21,16721,03521,12820,882
Diluted21,16721,03521,12820,882
Royalty [Member]    
Total revenue$ 17,054$ 17,795$ 35,057$ 40,380
License [Member]    
Total revenue$ 0$ 0$ 0$ 1,000

ENTA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 63,542$ 85,388
Short-term marketable securities236,768284,522
Accounts receivable7,7568,614
Prepaid expenses and other current assets10,93213,263
Income tax receivable32,03131,004
Total current assets351,029422,791
Property and equipment, net15,47911,919
Operating lease, right-of-use assets42,89422,794
Restricted cash3,9683,968
Other long-term assets187803
Total assets413,557462,275
Current liabilities:  
Accounts payable6,7264,097
Accrued expenses and other current liabilities10,63018,339
Liability related to the sale of future royalties33,67135,076
Operating lease liabilities3,5815,275
Total current liabilities54,60862,787
Liability related to the sale of future royalties, net of current portion147,776159,429
Operating lease liabilities, net of current portion43,41221,238
Series 1 nonconvertible preferred stock1,4231,423
Other long-term liabilities224663
Total liabilities247,443245,540
Commitments and contingencies (Note 11)
Stockholders' equity:  
Common stock; $0.01 par value per share, 100,000 shares authorized; 21,179 and 21,059 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively212211
Additional paid-in capital438,128424,693
Accumulated other comprehensive loss(667)(1,174)
Accumulated deficit(271,559)(206,995)
Total stockholders' equity166,114216,735
Total liabilities and stockholders' equity$ 413,557$ 462,275
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEenanta.com
 INDUSTRYBiotechnology
 EMPLOYEES160

Enanta Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Enanta Pharmaceuticals Inc? What does ENTA stand for in stocks?

ENTA is the stock ticker symbol of Enanta Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enanta Pharmaceuticals Inc (ENTA)?

As of Fri Jun 14 2024, market cap of Enanta Pharmaceuticals Inc is 271.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers. The fair value of Enanta Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enanta Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enanta Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ENTA is over valued or under valued. Whether Enanta Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Enanta Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENTA.

What is Enanta Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, ENTA's PE ratio (Price to Earnings) is -2.06 and Price to Sales (PS) ratio is 3.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enanta Pharmaceuticals Inc's stock?

In the past 10 years, Enanta Pharmaceuticals Inc has provided -0.111 (multiply by 100 for percentage) rate of return.